Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key Companies in the Market - SPARC, AbbVie, Ocuphire, Santen, Glaukos, Ocular Therapeutix, VivaVision Biotech, MediPrint Ophthalmics

According to DelveInsight's' estimates, the open-angle glaucoma market in the 7MM is expected to show positive growth, during the forecast period (2023–2032), mainly attributed to the launch of upcoming therapies and the increasing prevalence of open-angle glaucoma.

LAS VEGAS, Oct. 12, 2023 /PRNewswire/ -- DelveInsight's Open-Angle Glaucoma Market Insights report includes a comprehensive understanding of current treatment practices, open-angle glaucoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Open-Angle Glaucoma Market Report

• As per DelveInsight analysis, the open-angle glaucoma market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• As per DelveInsight assessment, the highest diagnosed prevalent cases of open-angle glaucoma was estimated in the US in 2022, with 2.2 million cases which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population. 
• Leading open-angle glaucoma companies such as Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others are developing novel open-angle glaucoma drugs that can be available in the open-angle glaucoma market in the coming years.
• Some key therapies for open-angle glaucoma treatment include NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others.

Discover which therapies are expected to grab the major open-angle glaucoma market share @ Open-Angle Glaucoma Market Report

Open-Angle Glaucoma Overview

Open-angle glaucoma is a prevalent and serious ocular condition that impacts the optic nerve, potentially leading to vision impairment or blindness if left unattended. It stands as the most widespread type of glaucoma and typically advances slowly over time, frequently without any discernible symptoms during its initial stages. This is why it's often referred to as the "silent thief of vision." Primary open-angle glaucoma (POAG) represents the most common subtype, progressing gradually with elevated intraocular pressure. Normal-tension glaucoma (NTG) results in optic nerve damage even with normal intraocular pressure, while juvenile open-angle glaucoma is a rare early-onset variant that emerges in childhood or early adulthood. In the early phases of open-angle glaucoma, noticeable symptoms or discomfort are typically absent. Peripheral vision loss usually emerges as the initial sign, occasionally going unnoticed as central vision remains unaffected. As the condition advances, tunnel vision can develop, and in severe instances, central vision loss may occur.

Open-Angle Glaucoma Epidemiology Segmentation

The open-angle glaucoma epidemiology section provides insights into the historical and current open-angle glaucoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The open-angle glaucoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalent Cases of Glaucoma
• Total Diagnosed Prevalent Cases of Glaucoma
• Type-specific Diagnosed Prevalent Cases of Glaucoma
• Type-specific Diagnosed Prevalent Cases of Open-Angle Glaucoma
• Gender-specific Diagnosed Prevalent Cases of Open-Angle Glaucoma
• Age-specific Diagnosed Prevalent Cases of Open-Angle Glaucoma 

Open-Angle Glaucoma Treatment Market 

The primary goal of open-angle glaucoma treatment is to lower intraocular pressure to prevent further damage to the optic nerve. This is typically achieved through a combination of medical, laser, or surgical interventions. Medical treatment often involves the use of eye drops that either reduce the production of aqueous humor or increase its drainage. These medications help lower intraocular pressure and are usually the first line of defense against glaucoma.

Laser therapy, such as selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT), can be employed to enhance the drainage of aqueous humor from the eye. These procedures are typically reserved for cases where eye drops alone are insufficient. In more advanced or refractory cases, surgical options like trabeculectomy or minimally invasive glaucoma surgery (MIGS) may be considered. These surgeries create a new drainage pathway for the aqueous humor to reduce intraocular pressure.

Effective open-angle glaucoma management often involves a combination of these approaches tailored to the individual patient's needs, with regular monitoring to ensure that the disease is well-controlled and that vision loss is prevented or minimized. Early detection and ongoing treatment are essential in preserving the patient's vision and quality of life.

To know more about open-angle glaucoma treatment, visit @ Open-Angle Glaucoma Treatment Drugs 

Key Open-Angle Glaucoma Therapies and Companies

• NCX-470: Nicox Ophthalmics
• PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)/Visiox Pharma
• TC-002 (latanoprost): TearClear
• iDose TR (Travoprost Intraocular Implant): Glaukos Corporation
• Sepetaprost/DE-126/ONO-9054/STN-1012600: Santen Inc/Ono Pharmaceutical
• Catioprost/DE-130A/STN1013001: Santen Pharmaceuticals
• Citicoline eye drops 2%: Omikron Italia S.r.l./OPIS Spain
• H-1337: D. Western Therapeutics Institute (DWTI)
• OTX-TIC: Ocular Therapeutix, Inc.
• LL-BMT1: MediPrint Ophthalmics (formerly Leo Lens Pharma)
• TRS01: Tarsier Pharma
• POLAT-001 (Liposomal latanoprost): Peregrine Ophthalmic
• Nyxol (Phentolamine Mesylate): Ocuphire Pharma
• QLS-101: Qlaris Bio, Inc.
• BTQ-1902: Betaliq, Inc.
• VVN539: VivaVision Biotech, Inc.
• AGN-193408: Abbvie

Learn more about the FDA-approved drugs for open-angle glaucoma @ Drugs for Open-Angle Glaucoma Treatment 

Open-Angle Glaucoma Market Dynamics

The dynamics of the open-angle glaucoma market are expected to change in the coming years. The surge in open-angle glaucoma cases prompts the need for enhanced treatment options. Increasing recognition of early detection's role in minimizing disease impact fuels higher screening and diagnosis rates. As awareness spreads and healthcare infrastructure improves, emerging markets hold promising opportunities for growth in the open-angle glaucoma market.

Furthermore, the open-angle glaucoma pipeline is very robust; many potential therapies are being investigated for the treatment of open-angle glaucoma, and it is safe to predict that the treatment space will significantly impact the open-angle glaucoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the open-angle glaucoma market in the 7MM.

However, several factors are impeding the growth of the open-angle glaucoma market. Inadequate patient adherence to lifelong medication and infrequent follow-up care can result in less-than-ideal treatment outcomes. Stringent regulatory protocols and approval procedures may impede the timely introduction of new treatments and innovations. Moreover, open-angle glaucoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the open-angle glaucoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the open-angle glaucoma market growth.

Scope of the Open-Angle Glaucoma Market Report

• Therapeutic Assessment: Open-Angle Glaucoma current marketed and emerging therapies
• Open-Angle Glaucoma Market Dynamics: Conjoint Analysis of Emerging Open-Angle Glaucoma Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Open-Angle Glaucoma Market Access and Reimbursement

Discover more about open-angle glaucoma drugs in development @ Open-Angle Glaucoma Clinical Trials

Table of Contents

Related Reports

Open-Angle Glaucoma Pipeline

Open-Angle Glaucoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key open-angle glaucoma companies, including Qlaris Bio, Ocular Therapeutix, SALVAT, Aerpio Pharmaceuticals, Ocularis Pharma, PolyActiva, AbbVie, Annexon, Skye Bioscience, GrayBug, Quark Pharmaceuticals, among others.

Open-Angle Glaucoma Epidemiology

Open-Angle Glaucoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted open-angle glaucoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Glaucoma Market

Glaucoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucoma companies, including Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, among others.

Glaucoma Pipeline

Glaucoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glaucoma companies, including Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision,  HK inno.N, Avirmax Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]   
+1(919)321-6187
www.delveinsight.com  

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED